Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026

/in

TX001 is an engineered Regenerative Macrophage Therapy for end-stage liver disease (ESLD) with anti-inflammatory and anti-fibrotic properties These new preclinical data demonstrate RTX001’s pharmacology, safety, tolerability, and efficacy in mouse models, with reduced fibrosis and inflammation observed Results confirm RTX001’s positive preclinical safety and therapeutic profile ahead of interim results from Resolution’s Phase I/II EMERALD […]

Read more

AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer

/in

Brings more than 20 years of neurology, clinical development, and translational experience as AstronauTx prepares to advance its lead programmes into clinical development AstronauTx also appoints Deb Gouveia as Vice President, Clinical Operations and Development Strategy to further strengthen clinical development capabilities London, UK, 12 May 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics […]

Read more

ViCentra Announces Commercial Launch of New Smartphone-Controlled Kaleido Automated Insulin Delivery Patch Pump System

/in

New system combines Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7, with first commercial deliveries in Germany and the Netherlands planned for later this summer Enables insulin automation to be controlled directly from the user’s smartphone, rather than a separate dedicated handset Starting on Kaleido today with Diabeloop’s DBLG1 algorithm is the fastest path to […]

Read more

Poolbeg Pharma plc – POLB 001 cancer immunotherapy-induced CRS patent granted in Canada

/in

Further strengthening of Poolbeg’s global intellectual property portfolio 11 May 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Canadian […]

Read more
Vianautis

ViaNautis Bio to present its targeted polyNaut® nanovesicles (tPNVs) for the generation of in vivo CAR-T therapies at ASGCT Annual Meeting

/in

Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’ proprietary, polymer-based delivery platform for oligonucleotides enabling cell‑specific targeting through nanobody conjugation CD8 nanobody conjugated tPNVs are simple to manufacture and display high stability at 4°C CD8-tPNVs precisely target CD8-expressing immune cells in vitro and in vivo after intravenous or subcutaneous administration Cambridge, UK – 7 May, 2026  – […]

Read more
© Optimum Strategic Communications.